{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:25Z","timestamp":1761101005857},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,1,11]],"date-time":"2010-01-11T00:00:00Z","timestamp":1263168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,1,11]],"date-time":"2010-01-11T00:00:00Z","timestamp":1263168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/bmt.2009.368","type":"journal-article","created":{"date-parts":[[2010,1,11]],"date-time":"2010-01-11T11:53:59Z","timestamp":1263210839000},"page":"1469-1470","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development of severe sclerotic chronic GVHD during treatment with dasatinib"],"prefix":"10.1038","volume":"45","author":[{"given":"D","family":"Pulanic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E W","family":"Cowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M R","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S Z","family":"Pavletic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,11]]},"reference":[{"key":"BFbmt2009368_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/bmt.2009.20","volume":"44","author":"M Breccia","year":"2009","unstructured":"Breccia M, Cannella L, Stefanizzi C, Carotti A, Santopietro M, Alimena G . Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? [letter] Bone Marrow Transplant 2009; 44: 331\u2013332.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009368_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/bmt.2008.252","volume":"42","author":"L Magro","year":"2008","unstructured":"Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I . Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008; 42: 757\u2013760.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2009368_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1182\/blood-2009-02-204750","volume":"114","author":"L Magro","year":"2009","unstructured":"Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Terriou L et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114: 719\u2013722.","journal-title":"Blood"},{"key":"BFbmt2009368_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","volume":"114","author":"A Olivieri","year":"2009","unstructured":"Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009; 114: 709\u2013718.","journal-title":"Blood"},{"key":"BFbmt2009368_CR5","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1182\/blood-2009-07-231159","volume":"114","author":"M Stadler","year":"2009","unstructured":"Stadler M, Ahlborn R, Kamal H, Diedrich H, Buchholz S, Eder M et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease [letter]. Blood 2009; 114: 3718\u20133719.","journal-title":"Blood"},{"key":"BFbmt2009368_CR6","first-page":"281","volume":"5","author":"DG Aguilera","year":"2009","unstructured":"Aguilera DG, Tsimberidou AM . Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 2009; 5: 281\u2013289.","journal-title":"Ther Clin Risk Manag"},{"key":"BFbmt2009368_CR7","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1096\/fj.07-105627","volume":"22","author":"A Akhmetshina","year":"2008","unstructured":"Akhmetshina A, Dees C, Pileckyte M, Maurer B, Axmann R, Jungel A et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008; 22: 2214\u20132222.","journal-title":"FASEB J"},{"key":"BFbmt2009368_CR8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/art.23436","volume":"58","author":"C Skhirtladze","year":"2008","unstructured":"Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum 2008; 58: 1475\u20131484.","journal-title":"Arthritis Rheum"},{"key":"BFbmt2009368_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1172\/JCI200419603","volume":"114","author":"CE Daniels","year":"2004","unstructured":"Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004; 114: 1308\u20131316.","journal-title":"J Clin Invest"},{"key":"BFbmt2009368_CR10","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","volume":"111","author":"AE Schade","year":"2008","unstructured":"Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366\u20131377.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2009368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009368","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2009368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:16:58Z","timestamp":1648037818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2009368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,11]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFbmt2009368"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2009.368","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,11]]},"assertion":[{"value":"11 January 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}